<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>Not provided</study_start_year><condition>Metastatic Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Metastatic Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2159360</full_dataset_link><study_start_month>Not provided</study_start_month><keyword>Capecitabine</keyword><repository>ECRIN MDR</repository><study_status>Not provided</study_status></additional><is_claimable>false</is_claimable><name>Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker</name><description>Colorectal cancer patients with metastases (mCRC) at response under first-line chemotherapy are candidates for an convenient maintenance treatment.</description><dates><creation>1900-01-01</creation></dates><accession>2159360</accession><cross_references><ClinicalTrials___gov>NCT02043821</ClinicalTrials___gov></cross_references></HashMap>